Keywords
Labetalol
Pregnancy-induced hypertension
Effect
Adverse pregnancy outcomes
Submitted : 2023-12-12
Accepted : 2023-12-27
Published : 2024-01-11
Abstract
Objective: To investigate the effect of magnesium sulfate combined with labetalol in treating hypertension in pregnancy (HIP) and its impact on adverse pregnancy outcomes. Methods: A total of 150 HIP patients treated at the Qujing Maternal and Child Healthcare Hospital from June 2020 to June 2023 were randomly assigned using the lottery method. They were divided into the control group (treated with magnesium sulfate alone, 75 cases), and the intervention group (magnesium sulfate + labetalol combined treatment, 75 cases). Blood pressure levels, total adverse reaction rates, total adverse pregnancy outcome rates, and total adverse fetal outcome rates were compared between the two groups. Results: Compared to the control group’s diastolic (87.94 ± 4.86 mmHg) and systolic (138.52 ± 9.23 mmHg) blood pressures, the intervention group showed lower levels of diastolic (78.95 ± 3.57 mmHg) and systolic (129.88 ± 7.47 mmHg) blood pressures (P < 0.05). The intervention group exhibited a lower total adverse reaction rate (4.00%) compared to the control group (14.67%; P < 0.05). Similarly, the total adverse pregnancy outcome rate in the intervention group (4.00%) was significantly lower than that in the control group (18.67%; P < 0.05). Furthermore, the total adverse fetal outcome rate in the intervention group (6.67%) was lower than that in the control group (22.67%; P < 0.05). Conclusion: The combination of magnesium sulfate and labetalol demonstrates significant efficacy in treating HIP. It effectively lowers blood pressure, improves pregnancy and fetal outcomes, is highly safe, and deserves promotion and application.
References
Yuan Y, 2021, Research on the Clinical Therapeutic Effect of Magnesium Sulfate Combined with a Nifedipine Treatment Regimen in Patients with Pregnancy-Induced Hypertension. Systems Medicine, 6(3): 138–140.
Liang Q, 2021, Clinical Observation on the Treatment of Pregnancy-Induced Hypertension Syndrome Using Integrated Traditional Chinese and Western Medicine. Journal of Practical Traditional Chinese Medicine, 37(10): 1739–1740.
Han Y, Sun M, Han Y, et al., 2020, Two Cases of Pregnancy-Induced Hypertension Syndrome Were Treated with Traditional Chinese Medicine. China Medical Herald, 17(5): 181–183 + 196.
Zhao L, Sun Y, Cong L, et al., 2022, Research on the Effect of Magnesium Sulfate Combined with Nifedipine in the Treatment of Pregnancy-Induced Hypertension. Journal of Practical Cardio-Cerebral and Pulmonary Vascular Diseases, 30(3): 103–107.
Sang Y, 2019, Observation on the Effectiveness and Safety of Magnesium Sulfate Combined with Labetalol in the Treatment of Severe Pregnancy-Induced Hypertension. Modern Diagnosis and Treatment, 30(17): 3070–3072.
Zhao Y, Zhao W, Jin J, 2022, Effects of Nifedipine Combined with Magnesium Sulfate Treatment on the Clinical Efficacy, Renal Function, and Pregnancy Outcomes of Pregnancy-Induced Hypertension. Sichuan Journal of Physiological Sciences, 44(8): 1447–1449.
He X, Zhi J, 2022, Research Progress on Pregnancy-Induced Hypertension Treatment and Medication Safety. Chinese Contemporary Medicine, 29(26): 40–43 + 47.
Wei W, Wang X, Tan G, et al., 2020, Research Progress on Susceptibility Genes for Pregnancy-Induced Hypertension. Progress in Modern Obstetrics and Gynecology, 29(6): 469–472.
Wang Z, Jia Q, Li R, et al., 2022, The Latest Research Progress in Drug Treatment of Patients with Pregnancy-Induced Hypertension. Systems Medicine, 7(13): 195–198.
Lu F, Gao F, Wang L, et al., 2021, Research Progress on Potential Markers and Possible Mechanisms of Placental Tissue in Pregnancy-Induced Hypertension. Journal of Henan Medical College, 33(5): 629–631.
Deng Y, 2021, Application of Labetalol in the Treatment of Patients with Pregnancy-Induced Hypertension and Analysis of Delivery Outcomes. Chinese Medicine and Clinic, 21(9): 1547–1549.
Qiang J, 2021, New Progress in Drug Treatment of Pregnancy-Induced Hypertension. Journal of Armed Police Logistics College (Medical Edition), 30(4): 144–147.
Jiang J, 2022, Effects of Magnesium Sulfate Combined with Nifedipine on Blood Pressure Control and Adverse Pregnancy Outcomes in Patients with Pregnancy-Induced Hypertension. Northern Pharmacy, 19(11): 61–63.
Ruan Y, Chen D, 2022, Effect of Labetalol, Nifedipine Combined with Magnesium Sulfate in Treating Pregnancy-Induced Hypertension and on IGF-?, IGF-?, and IGFBP-1. Chinese Medical Sciences, 12(22): 72–75 + 111.
Chen S, 2022, The Efficacy of Labetalol Combined with Magnesium Sulfate in Treating Pregnancy-Induced Hypertension and Its Effect on 24-hour Urinary Protein Quantification. Journal of Rare Diseases, 29(12): 59–60.